Oppenheimer Asset Management INC Boosted Holding in Bristol Myers Squibb Co (BMY) by $8.31 Million as Market Valuation Declined

December 14, 2017 - By Hazel Jackson

Investors sentiment decreased to 0.95 in 2017 Q2. Its down 0.03, from 0.98 in 2017Q1. It dropped, as 78 investors sold BMY shares while 520 reduced holdings. 120 funds opened positions while 451 raised stakes. 1.10 billion shares or 2.26% less from 1.12 billion shares in 2017Q1 were reported. First Allied Advisory Svcs has invested 0.18% in Bristol-Myers Squibb Company (NYSE:BMY). Private Advisor Gp Ltd Company accumulated 218,513 shares or 0.33% of the stock. Palisade Cap Ltd Nj owns 11,698 shares for 0.02% of their portfolio. Tradition Cap Mngmt accumulated 47,361 shares. 57,999 are owned by Laurion Cap Mgmt Lp. The Georgia-based Bowen Hanes And Inc has invested 0.03% in Bristol-Myers Squibb Company (NYSE:BMY). Los Angeles Management Equity Inc reported 0.5% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Rfg Advisory Gp Incorporated Limited Liability Com holds 0.15% or 9,961 shares in its portfolio. Massmutual Fsb Adv holds 0% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 9,065 shares. New York-based Tiedemann Wealth Mgmt Ltd Liability Company has invested 0.14% in Bristol-Myers Squibb Company (NYSE:BMY). Drexel Morgan And Communications invested in 9,298 shares or 0.53% of the stock. D L Carlson reported 0.12% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Neville Rodie And Shaw Inc invested in 95,938 shares or 0.61% of the stock. Daiwa Secs Gru Inc accumulated 0.06% or 154,556 shares. Wealthfront reported 29,175 shares.

Since September 6, 2017, it had 0 buys, and 1 sale for $560,400 activity.

Oppenheimer Asset Management Inc increased its stake in Bristol Myers Squibb Co (BMY) by 185.93% based on its latest 2017Q2 regulatory filing with the SEC. Oppenheimer Asset Management Inc bought 151,105 shares as the company’s stock declined 1.04% while stock markets rallied. The institutional investor held 232,376 shares of the major pharmaceuticals company at the end of 2017Q2, valued at $12.95M, up from 81,271 at the end of the previous reported quarter. Oppenheimer Asset Management Inc who had been investing in Bristol Myers Squibb Co for a number of months, seems to be bullish on the $103.88B market cap company. The stock increased 0.30% or $0.19 during the last trading session, reaching $63.47. About 4.35M shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since December 14, 2016 and is downtrending. It has underperformed by 39.89% the S&P500.

Oppenheimer Asset Management Inc, which manages about $12.85 billion and $3.62B US Long portfolio, decreased its stake in Pepsico Inc (NYSE:PEP) by 50,247 shares to 98,285 shares, valued at $11.35M in 2017Q2, according to the filing. It also reduced its holding in Aetna Inc New (NYSE:AET) by 23,908 shares in the quarter, leaving it with 28,817 shares, and cut its stake in Pnc Finl Svcs Group Inc (NYSE:PNC).

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Investorplace.com which released: “Bristol-Myers Squibb Co (BMY) Industry Group Rank Penalize Rating” on December 08, 2017, also Bloomberg.com with their article: “Bristol-Myers Cancer Drug Opdivo Shows Surprising HIV Impact” published on December 01, 2017, Businesswire.com published: “Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for …” on December 13, 2017. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Investorplace.com and their article: “Bristol-Myers Squibb Co (BMY) Earnings Growth Penalize Rating” published on December 01, 2017 as well as Investorplace.com‘s news article titled: “3 Big Stock Charts for Monday: Bank of America Corp (BAC), Bristol-Myers …” with publication date: December 04, 2017.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company had 69 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Equal-Weight” rating given on Friday, October 13 by Barclays Capital. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Buy” rating given on Wednesday, October 25 by Citigroup. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Buy” rating given on Friday, January 22 by Berenberg. The firm has “Market Perform” rating by BMO Capital Markets given on Wednesday, April 5. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Sell” rating by BMO Capital Markets on Monday, June 5. On Friday, August 19 the stock rating was maintained by UBS with “Buy”. Deutsche Bank maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Monday, July 17. Deutsche Bank has “Hold” rating and $55 target. As per Wednesday, December 2, the company rating was upgraded by Guggenheim. The company was maintained on Friday, September 22 by Piper Jaffray. As per Wednesday, August 16, the company rating was maintained by BMO Capital Markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.